title: Injectable fibroblast growth factor-2 coacervate for persistent angiogenesis.
abstract: Enhancing the maturity of the newly formed blood vessels is critical for the success of therapeutic angiogenesis. The maturation of vasculature relies on active participation of mural cells to stabilize endothelium and a basal level of relevant growth factors. We set out to design and successfully achieved robust angiogenesis using an injectable polyvalent coacervate of a polycation, heparin, and fibroblast growth factor-2 (FGF2). FGF2 was loaded into the coacervate at nearly 100% efficiency. In vitro assays demonstrated that the matrix protected FGF2 from proteolytic degradations. FGF2 released from the coacervate was more effective in the differentiation of endothelial cells and chemotaxis of pericytes than free FGF2. One injection of 500 ng of FGF2 in the coacervate elicited comprehensive angiogenesis in vivo. The number of endothelial and mural cells increased significantly, and the local tissue contained more and larger blood vessels with increased circulation. Mural cells actively participated during the whole angiogenic process: Within 7 d of the injection, pericytes were recruited to close proximity of the endothelial cells. Mature vasculature stabilized by vascular smooth muscle cells persisted till at least 4 wk. On the other hand, bolus injection of an identical amount of free FGF2 induced weak angiogenic responses. These results demonstrate the potential of polyvalent coacervate as a new controlled delivery platform.
authors.affiliation: Department of Bioengineering, University of Pittsburgh, Pittsburgh, PA 15261, USA.
authors.forename: Hunghao
authors.initials: H
authors.lastname: Chu
authors.forename: Jin
authors.initials: J
authors.lastname: Gao
authors.forename: Chien-Wen
authors.initials: CW
authors.lastname: Chen
authors.forename: Johnny
authors.initials: J
authors.lastname: Huard
authors.forename: Yadong
authors.initials: Y
authors.lastname: Wang
mesh_terms: D002454:Cell Differentiation; D002633:Chemotaxis; D004337:Drug Carriers / Q000737:chemistry* / Q000494:pharmacology; D042783:Endothelial Cells / Q000166:cytology; D016222:Fibroblast Growth Factor 2 / Q000008:administration & dosage*; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D018919:Neovascularization, Physiologic / Q000187:drug effects*; D020286:Pericytes
chemical_list: D004337:Drug Carriers; D016222:Fibroblast Growth Factor 2; D006493:Heparin